(Q50575342)

English

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin. (English)

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

Massimo Andreoni

9

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

Giovannino Ciccone

20

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

author name string

A Ciancio

1

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

A Picciotto

2

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

C Giordanino

3

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

A Smedile

4

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Tabone

5

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

A Manca

6

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

G Marenco

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

P Garbagnoli

8

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

G Cariti

10

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

G Calleri

11

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Sartori

12

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

S Cusumano

13

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

A Grasso

14

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

R Rizzi

15

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Gallo

16

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Basso

17

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Anselmo

18

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

G Percario

19

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

M Rizzetto

21

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

G Saracco

22

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

24

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

7

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

1079-1086

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Retreatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naïve patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Evaluation of amantadine in chronic hepatitis C: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03098.X

21 January 2018

Identifiers

10.1111/J.1365-2036.2006.03098.X

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

1 reference

Europe PubMed Central

15 March 2018

http://europepmc.org/abstract/MED/16984502

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50575342&oldid=1540654892"